Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 5—May 2023
Research

SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021

Shannon C. O’BrienComments to Author , Lyndsey D. Cole, Bernadette A. Albanese, Allison Mahon, Vijaya Knight, Nathan Williams, Rachel Severson, Alexis Burakoff, Nisha B. Alden, and Samuel R. Dominguez
Author affiliations: Colorado Department of Public Health and Environment, Denver, Colorado, USA (S.C. O’Brien, N. Williams, R. Severson, A. Burakoff, N.B. Alden); Children’s Hospital Colorado, Aurora, Colorado, USA (L.D. Cole, A. Mahon, V. Knight, S.R. Dominguez); Tri-County Health Department, Greenwood Village, Colorado, USA (B.A. Albanese)

Main Article

Table 2

SARS-CoV-2 serology results, seroprevalence, and seroprevalence ratios by racial/ethnic and age group, Colorado, USA, May 12-July 13, 2021*

Group Serology results, no.
 Seroprevalence, % (95% CI) Seroprevalence ratio (95% CI)
Seronegative Seropositive†
Total
 525
 304
 36.7 (33.4–40.1)
 NA
Race/ethnicity
Non-Hispanic White 218 72 24.8 (20.0–30.2) Referent
Hispanic all races 144 143 49.8 (43.9–55.8) 2.01 (1.59–2.53)‡
Non-Hispanic Black 66 40 37.7 (28.5–47.7) 1.52 (1.11–2.08)‡
Non-Hispanic other 64 35 35.4 (26.0–45.6) 1.42 (1.02–1.99)‡
Unknown
 33
 14
 29.8 (17.3–44.9)
 1.20 (0.74–1.94)
Age, y
1–4 155 99 39.0 (32.9–45.3) Referent
5–11 201 96 32.3 (27.0–38.0) 0.83 (0.66–1.04)
12–17 169 109 39.2 (33.4–45.2) 1.01 (0.81–1.24)

*NA, not applicable. †Seropositivity determined by presence of spike and/or nucleocapsid IgG. ‡Significant at p<0.05.

Main Article

1Preliminary results from this study were presented at the Council of State and Territorial Epidemiologists Conference; Louisville, Kentucky, USA; June 19–23, 2022.

Page created: March 27, 2023
Page updated: April 18, 2023
Page reviewed: April 18, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external